DRUG LEGALIZATION SERIES
PART 16
If you’re new to the series, start here.
How adult governments change policy without betting the farm.
Executive Summary
The drug debate keeps getting forced into a fake choice.
Either keep prohibition, keep the toxic supply, and keep pretending the death toll is the price of being “serious.”
Or flip everything at once and hope nobody notices the weak points until after the damage is done.
Adult governments do not run high-risk policy that way. They pilot, measure, and scale.
That is the argument in this chapter. A drug legalization pilot program is the responsible middle path between paralysis and recklessness. It lets governments test a narrow reform model, publish the results, tighten what fails, and expand only what proves it can reduce harm.
That matters because the United States still recorded 79,384 drug overdose deaths in 2024.[1]
The core claim is simple:
• A drug legalization pilot program should be narrow enough to audit.
• A tiered model should separate low-risk and high-risk lanes instead of pretending every substance belongs in the same channel.
• Risk-based drug regulation should govern the whole design.
• A regulated pharmacy model should carry the highest-risk lane.
• Treatment on demand should be real capacity, not a slogan.
• Diversion control, overdose prevention, public safety, and accountability should be built in from day one.
• Expansion should depend on outcomes, not politics.
This chapter is the practical answer to the series so far. Part 15 handled the objections. Part 16 handles the implementation question: what does drug policy reform look like when adults are actually running it?
This Chapter Builds on Earlier Parts
Part 1 made the basic case for regulation and harm reduction.
Part 1.5 clarified legalization vs. decriminalization vs. regulation.
Part 7 explained the recovery lockbox funding idea.
Part 8 showed why fear-based drug policy keeps failing.
Part 9 laid out risk-based drug regulation.
Part 10 explained why accountability still exists in a regulated system.
Part 11 covered evidence-based prevention.
Part 12 covered the reentry overdose window.
Part 13 covered addiction, mental health, and homelessness.
Part 14 proposed the regulated pharmacy model.
Part 15 answered the hardest objections. Part 16 answers the next question: how do you actually move policy without betting the farm?
Why a Drug Legalization Pilot Program Is the Only Responsible Path
A drug legalization pilot program is not a soft version of reform. It is how serious governments test high-risk change without pretending they already know everything.
That is already how public systems handle uncertainty. Section 1115 demonstrations let states test new substance use disorder approaches while tying flexibility to metrics, monitoring, and evaluation.[3][4] CDC’s evaluation framework makes the same point from the public health side: define the program, gather credible evidence, support conclusions, and use the results.[5][6]
Drug policy should not be the one field where people are expected to choose between permanent failure and statewide improvisation.
A credible drug legalization pilot program should do four things before launch:
• define the population, geography, and time frame
• state what is being tested and what is out of scope
• publish the scoreboard up front
• write the stop, tighten, and scale triggers before politics get loud
If you cannot say what would count as failure, you do not have reform. You have theater.
This is where a lot of reform efforts get sloppy. They launch something broad, underfund it, measure it badly, and then act shocked when the backlash arrives. Oregon’s Measure 110 fight is a reminder that weak coordination and unclear results can destroy trust even when reform starts with good intentions.[7]
That is why this chapter takes a harder line. Evidence matters. Measurement matters. Accountability matters. If the pilot improves overdose prevention but creates obvious new harms, it should be tightened. If it fails after tightening, it should be stopped. If it works, it should scale.
That is not caution for the sake of caution. That is adult governance.
Designing the Pilot With Risk-Based Drug Regulation
The biggest design mistake in this debate is pretending all drugs belong in one bucket.
They do not.
Risk-based drug regulation works because it starts from reality. Different substances create different overdose risks, different dependence risks, different impairment risks, and different public-order risks. A serious reform model has to reflect that.
For a pilot, the cleanest approach is a two-lane structure.
Lane One: Lower-risk adult access under tight rules
This means:
• adult-only access
• testing and labeling
• purchase limits
• packaging standards
• strong penalties for fraud, contamination, and sales to minors
• clear rules on advertising and product appeal
That is not lax access. That is structured adult access.
Lane Two: The highest-risk lane
This is where the regulated pharmacy model belongs.
The regulated pharmacy model should include:
• narrow eligibility
• conservative quantities
• identity verification
• inventory tracking
• regular check-ins
• anomaly detection
• direct offers of treatment on demand
That is the simplest way to say it: as risk rises, structure rises with it.
Without risk-based drug regulation, pilots get sloppy fast. The public hears “legalization” and assumes one rule for everything. That is exactly what a serious model should reject. Lower-risk substances do not belong in the same lane as the highest-risk substances. Different risks require different controls.
That is also why this model is more politically defensible than blanket reform. It does not lie about risk. It does not pretend fentanyl and cannabis belong on the same shelf. It does not act like the only choices are prohibition forever or commercial chaos.
Risk-based drug regulation is the backbone that lets reform stay honest.
Why the Regulated Pharmacy Model Fits the High-Risk Lane
Part 14 made the larger case for the regulated pharmacy model. The implementation case is even simpler: the regulated pharmacy model is the narrowest, most auditable way to test the highest-risk lane.
That pharmacy-based lane matters for five reasons.
First, the regulated pharmacy model keeps the highest-risk lane inside institutions that already know how to handle dosing, identity verification, inventory, adverse-event monitoring, and recordkeeping.
Second, the regulated pharmacy model is easier to tighten or shut down than a loose commercial system.
Third, it creates natural points for treatment on demand. Every encounter becomes a chance to offer medication treatment, mental health care, recovery support, and housing referral.
Fourth, it makes diversion control more realistic. Not perfect. Realistic.
Fifth, it is more politically passable. A tightly controlled medicalized lane is easier to defend than broad retail access for the highest-risk substances.
This matters because the argument here is not “just legalize it and hope.” The argument is that the highest-risk lane should start in the narrowest, most measurable environment possible.
That is exactly what a regulated pharmacy model does.
It also aligns with the larger series argument that reform should move toward overdose prevention, care access, and measurable public safety gains rather than endless punishment theater. If a person is already at high overdose risk, leaving them in the illegal market is not the cautious option. It is the familiar failure.
What Still Gets Enforced: Public Safety, Diversion Control, and Accountability
One reason reform loses support is that opponents act like legalization means no enforcement.
That is nonsense.
A serious drug legalization pilot program keeps strong enforcement for behavior that harms other people.
That means strict enforcement for:
• unlicensed sales and trafficking
• sales to minors
• violence and coercion
• fraud and tampered products
• drug-impaired driving
• organized evasion of the pilot rules
That is what public safety is supposed to mean.
In other words, reform should stop using simple possession as the main enforcement target and start enforcing conduct that actually creates victims. That is not permissiveness. That is smarter targeting.
This is where diversion control has to be treated as a design issue, not a talking point.
A credible pilot should build diversion control into the structure through:
• identity verification
• limited quantities in the high-risk lane
• audit trails
• unusual-pattern alerts
• rapid compliance reviews
• escalating sanctions for providers or sites
• criminal penalties for coercion, fraud, or sales to minors
That is what accountability looks like under reform. It is not “anything goes.” It is rules, audits, consequences, and correction.
And that matters politically. Voters need to hear, clearly, that reform does not mean public disorder gets ignored. It means enforcement stops centering on low-level possession and gets refocused on the behavior that actually endangers other people.
That is a better use of law. It is also a more honest definition of public safety.
Treatment on Demand Has to Be Capacity, Not Theater
This is where reform models usually get exposed.
Everybody says people should get treatment. Then somebody finally asks for help and gets a waitlist, a voicemail, or a referral maze.
Treatment on demand is not rhetoric. It is a measurable capacity promise.
A serious pilot should lock in treatment on demand before launch, not after the ribbon cutting. That means real contracts, real slots, real staff, and real reporting.
Treatment on demand should include:
• same-day triage when possible
• medications for opioid use disorder where indicated[12][13]
• outpatient care
• intensive outpatient care
• residential placement when clinically appropriate
• warm handoffs from emergency departments, outreach teams, and pilot sites
• telehealth backup where geography or staffing creates gaps
San Francisco’s Treatment on Demand reporting is useful because it treats access as a system obligation that should be measured, not merely promised.[19]
This is also where a Medicaid 1115 waiver can matter. States already use Medicaid 1115 waiver authority to test substance use disorder delivery changes with required monitoring and evaluation.[3][4] Even when a pilot is not built entirely through a Medicaid 1115 waiver, that posture is still the right one: test, measure, report, and correct.
Without that backbone, critics are right to be skeptical. If reform changes access rules but leaves the care system broken, then people keep cycling through crisis and the pilot loses public trust fast.
So this has to be stated plainly: treatment on demand is not a side benefit. It is core infrastructure.
The Scoreboard: What an Evidence-Based Drug Policy Pilot Must Measure
If you measure the wrong thing, you reward the wrong behavior.
If you measure nothing, the loudest critic writes the story for you.
That is why evidence-based drug policy starts with the scoreboard.
A real pilot should publish a simple quarterly dashboard that an ordinary voter can understand. Not a 200-page PDF nobody reads. A scoreboard.
Overdose prevention
• fatal overdoses
• nonfatal overdoses
• overdose reversals
• overdose-related emergency department visits
• toxicology and contamination signals where available
Public safety
• violent crime around pilot areas
• calls for service
• public-use complaints where relevant
• sales to minors
• drug-impaired driving patterns
Diversion control
• audit pass or fail rates
• irregular inventory patterns
• confirmed diversion incidents
• sanctions issued
• license suspensions or corrective actions
Care access and outcomes
• time to intake
• treatment starts
• treatment retention at 30, 90, and 180 days
• repeat overdose after discharge
• successful warm handoffs
System performance
• cost per participant
• cost per meaningful outcome
• staffing gaps
• wait times
• rate of referrals that actually turn into care
This is the part of the debate that gets too emotional too fast. Good harm reduction pilot programs do not survive on moral argument alone. They survive when the numbers show real benefits and the public can see them.
That is also why local measurement matters. Research on supervised consumption services and drug consumption rooms suggests reductions in overdose harm and better links to care in multiple settings.[17][18] But “evidence elsewhere” is not enough by itself. A local pilot still has to prove it works in local conditions.
That is what evidence-based drug policy actually means.
Legal Pathways: Where a Medicaid 1115 Waiver Fits and Where Federal Law Still Matters
A serious reform plan has to be honest about federal constraints.
The Controlled Substances Act is real.[2] States cannot just wave it away because the policy case sounds compelling. If a pilot touches a federally controlled substance outside existing lawful channels, the state will need a lawful federal path in parallel.
That does not kill the pilot idea. It just means the pilot has to be built in layers.
Layer One: What states can build now
• governance and independent evaluation
• treatment on demand capacity
• audit rules and diversion control systems
• public dashboards
• lower-risk retail regulation where state authority already exists
• enforcement priorities focused on public safety outcomes
• reimbursement and evaluation structures linked to a Medicaid 1115 waiver where appropriate
Layer Two: What may require federal cooperation
• broader access models involving federally scheduled substances outside current rules
• rescheduling or other federal permission for certain distribution models
• changes that move beyond current medical or research pathways
This is where a Medicaid 1115 waiver is useful even beyond Medicaid itself. A Medicaid 1115 waiver is already a normal way for states to test and evaluate substance use disorder delivery changes.[3][4] That makes it politically and administratively familiar.
So no, a Medicaid 1115 waiver is not the whole answer. But it is a real tool inside the answer, and it reinforces the larger point of this chapter: build the testable parts now, measure them honestly, and expand only when the evidence and the law support the next step.
That is how reform avoids legal fantasy.
Funding, Privacy, and Scaling: Value-Based Payment, Pay-for-Success, and 42 CFR Part 2
A bad funding model pays for motion.
A good funding model pays for outcomes.
That is where value-based payment matters. CMS’s Value in Treatment demonstration tested a care management fee and a performance-based incentive for opioid use disorder treatment.[9] SAMHSA has also outlined how value-based payment can improve coordinated substance use disorder services when it is designed correctly.[10]
That matters because a pilot should not reward empty volume. It should reward engagement, retention, and lower repeat crisis rates.
A strong pilot can use value-based payment for:
• treatment providers
• emergency departments
• care navigation teams
• recovery support coordination
• post-overdose linkage systems
Then there is expansion funding.
This is where pay-for-success matters. Treasury’s SIPPRA model ties payment to predetermined results validated by an independent evaluator.[11] That is exactly the right posture for politically sensitive reform. Pay-for-success makes expansion contingent on performance instead of promises.
Used correctly, pay-for-success does three things:
• it makes scaling more politically credible
• it disciplines wishful thinking
• it forces the model to prove itself before it spreads
Privacy matters just as much. People do not seek care if care feels like a trap.
That is why 42 CFR Part 2 belongs in the architecture from the beginning. HHS updated 42 CFR Part 2 in 2024, and compliance with the final rule was required by February 16, 2026.[8]
The privacy rules for a pilot should be blunt and simple:
• patient-level treatment data stays protected
• dashboards use aggregated data
• evaluators get the minimum data necessary
• treatment participation databases should not become open law-enforcement databases
You can measure the system without creating a surveillance state.
Then publish the scaling rules.
Scale when overdose prevention improves, treatment engagement improves, public safety is stable, and diversion control stays within clear limits.
Tighten when youth access violations appear, disorder rises, or audit failures cluster around a site.
Stop when outcomes keep worsening after corrective action, fraud becomes systemic, or the treatment backbone is not there.
That is the point of a drug legalization pilot program. Not to bet the farm. To earn the next step.
The Bottom Line
The best case for this pilot-first approach is not that reform is risk-free.
It is that prohibition has already proven it can produce a toxic supply, black-market violence, mass death, and a huge gap between crisis and care.
So the real question is not whether reform carries risk.
The real question is whether we are mature enough to manage that risk better than the illegal market does.
That is why this chapter lands here:
• drug legalization should move through a drug legalization pilot program, not a leap of faith
• risk-based drug regulation should separate the lanes
• harm reduction pilot programs should be measured in public
• the regulated pharmacy model should handle the highest-risk lane
• treatment on demand should exist before launch, not after failure
• Medicaid 1115 waiver tools should be used where they fit
• value-based payment and pay-for-success should reward outcomes, not cycling
• 42 CFR Part 2, diversion control, overdose prevention, public safety, and accountability should be built in from the start
That is not soft. It is not reckless. It is what adult governance looks like.
If you want to follow the full series as it publishes, visit the blog.
If you prefer audio conversations on recovery, reentry, and purpose, check the podcast page.
And if you want the longer story behind why I write about this, start here.
Frequently Asked Questions
What makes a drug legalization pilot program safer than broad immediate legalization?
A drug legalization pilot program is safer because it limits scope, publishes metrics, uses independent evaluation, and writes tightening or shutdown triggers before launch. It replaces guesswork with governance.
Why is risk-based drug regulation central to this model?
Because risk-based drug regulation assigns tighter controls as risk rises. Lower-risk substances may fit strict retail channels. Higher-risk substances need narrower medicalized access with stronger safeguards.
Why use a regulated pharmacy model in the high-risk lane?
The regulated pharmacy model is easier to audit, easier to connect to care, easier to monitor for diversion control, and easier to tighten if problems emerge. It is the most defensible place to start the highest-risk lane.
Where does a Medicaid 1115 waiver fit into the pilot?
A Medicaid 1115 waiver is a real mechanism states already use to test and evaluate substance use disorder delivery changes.[3][4] Even outside Medicaid, the logic is useful: test, measure, report, and correct.
What does pay-for-success add that normal funding does not?
Pay-for-success makes expansion politically credible by tying payment to verified outcomes instead of promises.[11]
How do harm reduction pilot programs earn public trust?
Harm reduction pilot programs earn trust by publishing the scoreboard: overdoses, treatment engagement, complaints, sanctions, audit results, and neighborhood indicators. If the public cannot see the results, the public will not trust the model.
Where does someone go for help right now?
A good place to start is SAMHSA’s treatment locator or local crisis and treatment referral systems. But the larger point of this chapter is that help should not depend on luck. Treatment on demand should be built into the system.
References
[1] Centers for Disease Control and Prevention, National Center for Health Statistics. U.S. Life Expectancy Hits Record High as Drug Overdose Deaths Decline in 2024. https://www.cdc.gov/nchs/pressroom/releases/20260129.html
[2] U.S. Drug Enforcement Administration. The Controlled Substances Act. https://www.dea.gov/drug-information/csa
[3] Medicaid.gov. Substance Use Disorder Section 1115 Demonstration Opportunity. https://www.medicaid.gov/medicaid/section-1115-demonstrations/substance-use-disorder-section-1115-demonstration-opportunity
[4] Centers for Medicare & Medicaid Services. CMS Strengthens Monitoring and Evaluation Expectations for Medicaid 1115 Demonstrations. https://www.cms.gov/newsroom/press-releases/cms-strengthens-monitoring-evaluation-expectations-medicaid-1115-demonstrations
[5] Centers for Disease Control and Prevention. CDC Program Evaluation Framework. https://www.cdc.gov/evaluation/php/evaluation-framework/index.html
[6] Centers for Disease Control and Prevention. Framework for Program Evaluation in Public Health. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4811a1.htm
[7] Oregon Secretary of State Audits Division. Oregon Health Authority: Measure 110 Lacks Stability, Coordination, and Clear Results. https://sos.oregon.gov/audits/Pages/audit-2025-29-OHA.aspx
[8] U.S. Department of Health and Human Services. Fact Sheet: 42 CFR Part 2 Final Rule. https://www.hhs.gov/hipaa/for-professionals/regulatory-initiatives/fact-sheet-42-cfr-part-2-final-rule/index.html
[9] Centers for Medicare & Medicaid Services. Value in Opioid Use Disorder Treatment Demonstration Program. https://www.cms.gov/priorities/innovation/innovation-models/value-in-treatment-demonstration
[10] Substance Abuse and Mental Health Services Administration. Exploring Value-Based Payment for Substance Use Disorder Services in the United States. https://library.samhsa.gov/product/exploring-value-based-payment-substance-use-disorder-services-united-states/pep23-06-07-001
[11] U.S. Department of the Treasury. SIPPRA – Pay for Results. https://home.treasury.gov/services/social-impact-partnerships/sippra-pay-for-results
[12] Centers for Disease Control and Prevention. Opioid Use Disorder: Treating. https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html
[13] National Institute on Drug Abuse. Medications for Opioid Use Disorder. https://nida.nih.gov/research-topics/medications-opioid-use-disorder
[14] Health Canada. Safer Supply: Prescribed medications as a safer alternative to toxic illegal drugs. https://www.canada.ca/en/health-canada/services/opioids/responding-canada-opioid-crisis/safer-supply.html
[15] Nguyen HV, Mital S, Bugden S, McGinty EE. British Columbia’s Safer Opioid Supply Policy and Opioid Outcomes. JAMA Internal Medicine. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2814103
[16] Olding M, Rudzinski K, Schmidt R, et al. Perspectives on Diversion of Medications From Safer Opioid Supply Programs. JAMA Network Open. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2828220
[17] Marshall BDL, Milloy MJ, Wood E, Montaner JSG, Kerr T. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. https://pubmed.ncbi.nlm.nih.gov/21497898/
[18] European Union Drugs Agency. Drug consumption rooms: an overview of provision and evidence. https://www.euda.europa.eu/topics/pods/drug-consumption-rooms_en
[19] San Francisco Department of Public Health. Treatment on Demand FY2021–22 Report. https://media.api.sf.gov/documents/Treatment_on_Demand_Prop_T_FY2021-22_2.pdf
